{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:50:06Z","timestamp":1777945806523,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T00:00:00Z","timestamp":1211932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T00:00:00Z","timestamp":1211932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"abstract":"<jats:p>Seclazone possesses anti-inflammatory, analgesic and antipyretic properties. It effectively suppresses the development of adjuvant-induced polyarthritis in rats and the serum protein alterations associated with this condition. Seclazone also prevents phlogistic responses induced in rats by carrageenan. The anti-inflammatory effect of seclazone is not mediated by adrenocortical or pituitary stimulation since activity persists in adrenalectomized or hypophysectomized animals. Seclazone has an appreciable anti-bradykinin action in vitro. The drug is free of ulcerogenic activity at therapeutically active levels and possesses diuretic properties.<\/jats:p>","DOI":"10.1159\/000136381","type":"journal-article","created":{"date-parts":[[2008,5,30]],"date-time":"2008-05-30T03:28:44Z","timestamp":1212118124000},"page":"164-176","source":"Crossref","is-referenced-by-count":9,"title":["The Pharmacological Properties of Seclazone (7-chloro-3,3a-dihydro-2H, 9H-isoxazolo [3,2-b] [1,3] benzoxazin-9-one) A New Anti-Inflammatory Agent"],"prefix":"10.1159","author":[{"given":"F.M.","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.M.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Diamantis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kletzkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.J.","family":"Plekss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.D.","family":"Sofia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,5,28]]},"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/136381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000136381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:30:03Z","timestamp":1777728603000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000136381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,28]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000136381","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"value":"0031-7012","type":"print"},{"value":"1423-0313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,28]]}}}